CN109640992A - 治疗卵巢癌的方法 - Google Patents

治疗卵巢癌的方法 Download PDF

Info

Publication number
CN109640992A
CN109640992A CN201780051916.1A CN201780051916A CN109640992A CN 109640992 A CN109640992 A CN 109640992A CN 201780051916 A CN201780051916 A CN 201780051916A CN 109640992 A CN109640992 A CN 109640992A
Authority
CN
China
Prior art keywords
patient
cancer
lapani
therapy
parp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780051916.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·赫德利
R·马特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tesaro Inc
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109640992(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of CN109640992A publication Critical patent/CN109640992A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201780051916.1A 2016-06-29 2017-06-29 治疗卵巢癌的方法 Pending CN109640992A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662356461P 2016-06-29 2016-06-29
US62/356,461 2016-06-29
US201662402427P 2016-09-30 2016-09-30
US62/402,427 2016-09-30
US201762470141P 2017-03-10 2017-03-10
US62/470,141 2017-03-10
PCT/US2017/040039 WO2018005818A1 (en) 2016-06-29 2017-06-29 Methods of treating ovarian cancer

Publications (1)

Publication Number Publication Date
CN109640992A true CN109640992A (zh) 2019-04-16

Family

ID=60787744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780051916.1A Pending CN109640992A (zh) 2016-06-29 2017-06-29 治疗卵巢癌的方法

Country Status (24)

Country Link
US (5) US12383542B2 (https=)
EP (2) EP3478286B1 (https=)
JP (2) JP7083760B2 (https=)
KR (2) KR20230042136A (https=)
CN (1) CN109640992A (https=)
AU (1) AU2017290244B2 (https=)
BR (1) BR112018077492A2 (https=)
CA (1) CA3029671C (https=)
DK (1) DK3478286T3 (https=)
ES (1) ES2969816T3 (https=)
FI (1) FI3478286T3 (https=)
HR (1) HRP20240136T1 (https=)
HU (1) HUE064978T2 (https=)
IL (1) IL263925B2 (https=)
LT (1) LT3478286T (https=)
MX (1) MX394062B (https=)
NZ (1) NZ749413A (https=)
PL (1) PL3478286T3 (https=)
PT (1) PT3478286T (https=)
RS (1) RS65180B1 (https=)
SG (1) SG11201811564QA (https=)
SI (1) SI3478286T1 (https=)
SM (1) SMT202400105T1 (https=)
WO (1) WO2018005818A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115253066A (zh) * 2022-07-21 2022-11-01 湖南安泰康成生物科技有限公司 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置
CN115335085A (zh) * 2020-01-13 2022-11-11 格兰达利斯有限公司 用编码gm-csf的多核苷酸和额外药剂治疗癌症的方法
CN116092631A (zh) * 2023-01-17 2023-05-09 湖南安泰康成生物科技有限公司 铁死亡诱导剂与电场联用的肿瘤治疗系统

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230042136A (ko) 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CA3041684C (en) 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
MX2019008208A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-tim-3.
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
BR112019020211A2 (pt) 2017-03-27 2020-04-22 Tesaro, Inc. composições de niraparib
KR102582624B1 (ko) 2017-04-24 2023-09-22 테사로, 인코포레이티드 니라파립의 제조 방법
TWI879716B (zh) * 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. COMBINATION THERAPIES FOR TREATMENT OF CANCER
SG11202002499TA (en) 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof
AU2019215450A1 (en) * 2018-02-05 2020-08-27 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
US12036222B2 (en) * 2018-04-04 2024-07-16 The Wistar Institut of Anatomy and Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor
WO2020072797A1 (en) 2018-10-03 2020-04-09 Tesaro, Inc. Niraparib salts
US20210347758A1 (en) 2018-10-03 2021-11-11 Tesaro, Inc. Crystalline Forms of Niraparib Freebase
US10395772B1 (en) 2018-10-17 2019-08-27 Tempus Labs Mobile supplementation, extraction, and analysis of health records
US11640859B2 (en) 2018-10-17 2023-05-02 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
US10957433B2 (en) 2018-12-03 2021-03-23 Tempus Labs, Inc. Clinical concept identification, extraction, and prediction system and related methods
WO2020142583A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
US11705226B2 (en) 2019-09-19 2023-07-18 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
TW202116316A (zh) * 2019-07-15 2021-05-01 美商提薩羅有限公司 治療卵巢、輸卵管及腹膜癌之方法
US11295841B2 (en) * 2019-08-22 2022-04-05 Tempus Labs, Inc. Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data
JP2023508996A (ja) * 2019-12-31 2023-03-06 キネート バイオファーマ インク． Ｃｄｋ１２／１３阻害剤を用いる癌の処置
UY39201A (es) * 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib
EP4237090B1 (en) * 2020-10-29 2026-02-18 Board of Regents, The University of Texas System Methods for the detection and treatment of ovarian cancer
KR102858757B1 (ko) 2022-01-25 2025-09-10 서울대학교산학협력단 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법
WO2023159066A1 (en) 2022-02-15 2023-08-24 Tesaro, Inc. Use of niraparib for the treatment of brain cancer
CN121866063A (zh) * 2023-09-19 2026-04-14 上海瑛派药业有限公司 Parp抑制剂在卵巢癌维持治疗中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100009930A1 (en) * 2007-11-12 2010-01-14 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in conbination with anti-tumor agents
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CN105384695A (zh) * 2014-08-22 2016-03-09 四川海思科制药有限公司 嘧啶衍生物及其制备方法和在医药上的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007733B1 (en) 2006-04-03 2016-05-25 MSD Italia S.r.l. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
CA2702429A1 (en) 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
US8500933B2 (en) 2007-12-14 2013-08-06 Guardian Industries Corp. Localized heating of edge seals for a vacuum insulating glass unit, and/or unitized oven for accomplishing the same
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
ES2572652T3 (es) 2009-08-26 2016-06-01 Cephalon, Inc. Nuevas formas de un compuesto multicíclico
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2011153383A1 (en) 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
DK3327148T3 (da) 2010-06-18 2021-04-12 Myriad Genetics Inc Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
CA2779052A1 (en) 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
ES2658867T3 (es) 2012-06-07 2018-03-12 Institut Curie Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
WO2014052550A1 (en) * 2012-09-27 2014-04-03 Thomas Jefferson University Use of parp inhibitors to treat breast cancer
CA2893280A1 (en) 2012-11-28 2014-06-05 Sloan-Kettering Institute For Cancer Research Compositions and methods for the treatment of cancers associated with a deficiency in the mre11/rad50/nbs1 dna damage repair complex
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
US9850542B2 (en) 2013-03-04 2017-12-26 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (HR) deficient cancer
DK2981624T3 (da) * 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
EP3094752A4 (en) 2014-01-16 2017-08-16 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
EA201691376A1 (ru) 2014-02-04 2017-01-30 Пфайзер Инк. Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака
CA2941161A1 (en) 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
US20150344968A1 (en) * 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
CA2959072C (en) 2014-08-25 2025-12-09 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
HK1251474A1 (zh) 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
PL3954690T3 (pl) 2015-07-02 2023-08-14 Acerta Pharma B.V. Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌
CA3014252A1 (en) 2016-02-12 2017-08-17 Nantomics, Llc High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
US11154538B2 (en) * 2016-02-29 2021-10-26 Synta Pharmaceuticals Corporation Combination therapy for treatment of ovarian cancer
KR20230042136A (ko) 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
CN106496187A (zh) 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432055A (zh) 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法
KR20190130625A (ko) 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
BR112019020211A2 (pt) 2017-03-27 2020-04-22 Tesaro, Inc. composições de niraparib
KR102582624B1 (ko) 2017-04-24 2023-09-22 테사로, 인코포레이티드 니라파립의 제조 방법
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
WO2019005762A1 (en) 2017-06-26 2019-01-03 Abbvie Inc. TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
SG11202006147SA (en) 2017-12-27 2020-07-29 Tesaro Inc Methods of treating cancer
TW202116316A (zh) 2019-07-15 2021-05-01 美商提薩羅有限公司 治療卵巢、輸卵管及腹膜癌之方法
KR102336493B1 (ko) 2019-11-22 2021-12-07 주식회사 메디풀 항균탈취 조성물 및 이의 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100009930A1 (en) * 2007-11-12 2010-01-14 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in conbination with anti-tumor agents
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CN105384695A (zh) * 2014-08-22 2016-03-09 四川海思科制药有限公司 嘧啶衍生物及其制备方法和在医药上的应用

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JONATHAN LEDERMANN 等: "Olaparib Maintenance Therapyin Platinum-Sensitive Relapsed Ovarian Cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, pages 1382 - 1392 *
M WILLIAM AUDEH: "Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition", 《PHARMACOGENOMICS AND PERSONALIZED MEDICINE》 *
M WILLIAM AUDEH: "Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition", 《PHARMACOGENOMICS AND PERSONALIZED MEDICINE》, vol. 7, 3 October 2014 (2014-10-03), pages 307 - 316, XP055451834, DOI: 10.2147/PGPM.S39765 *
M.R. MIRZA 等: "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *
M.R. MIRZA 等: "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer", 《THE NEW ENGLAND JOURNAL OF MEDICINE》, 8 October 2016 (2016-10-08), pages 2154 - 2164 *
SHAHNEEN K SANDHU 等: "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial", 《LANCET ONCOL》 *
SHAHNEEN K SANDHU 等: "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial", 《LANCET ONCOL》, vol. 14, 28 June 2013 (2013-06-28), pages 882 - 892, XP055407449, DOI: 10.1016/S1470-2045(13)70240-7 *
URSULA MATULONIS 等: "A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer(ENGOT-OV16/NOVA trial).", 《JOURNAL OF CLINICAL ONCOLOGY》 *
URSULA MATULONIS 等: "A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer(ENGOT-OV16/NOVA trial).", 《JOURNAL OF CLINICAL ONCOLOGY》, vol. 32, no. 15, 20 May 2014 (2014-05-20), pages 1 - 4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115335085A (zh) * 2020-01-13 2022-11-11 格兰达利斯有限公司 用编码gm-csf的多核苷酸和额外药剂治疗癌症的方法
CN115253066A (zh) * 2022-07-21 2022-11-01 湖南安泰康成生物科技有限公司 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置
CN116092631A (zh) * 2023-01-17 2023-05-09 湖南安泰康成生物科技有限公司 铁死亡诱导剂与电场联用的肿瘤治疗系统

Also Published As

Publication number Publication date
EP3478286A1 (en) 2019-05-08
HUE064978T2 (hu) 2024-04-28
AU2017290244B2 (en) 2023-03-02
ES2969816T3 (es) 2024-05-22
EP3478286A4 (en) 2020-03-18
AU2017290244A1 (en) 2019-01-24
LT3478286T (lt) 2024-04-25
WO2018005818A1 (en) 2018-01-04
SI3478286T1 (sl) 2024-03-29
PT3478286T (pt) 2024-01-31
IL263925B1 (en) 2023-08-01
SMT202400105T1 (it) 2024-05-14
IL263925A (en) 2019-01-31
JP2022031478A (ja) 2022-02-18
MX394062B (es) 2025-03-19
JP2019524690A (ja) 2019-09-05
HRP20240136T1 (hr) 2024-04-12
KR20190029618A (ko) 2019-03-20
SG11201811564QA (en) 2019-01-30
US20220175751A1 (en) 2022-06-09
US20220395493A1 (en) 2022-12-15
DK3478286T3 (da) 2024-01-29
EP3478286B1 (en) 2024-01-03
NZ749413A (en) 2023-05-26
US20180311224A1 (en) 2018-11-01
IL263925B2 (en) 2023-12-01
BR112018077492A2 (pt) 2019-04-09
EP4302835A2 (en) 2024-01-10
PL3478286T3 (pl) 2024-04-22
JP7083760B2 (ja) 2022-06-13
RS65180B1 (sr) 2024-03-29
CA3029671A1 (en) 2018-01-04
MX2018016193A (es) 2019-06-10
US12527780B2 (en) 2026-01-20
US12383542B2 (en) 2025-08-12
KR20230042136A (ko) 2023-03-27
CA3029671C (en) 2023-08-15
FI3478286T3 (fi) 2024-03-14
US20240058319A1 (en) 2024-02-22
EP4302835A3 (en) 2024-03-20
US20220175752A1 (en) 2022-06-09
KR102510996B1 (ko) 2023-03-16

Similar Documents

Publication Publication Date Title
CN109640992A (zh) 治疗卵巢癌的方法
Wiggans et al. Poly (ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
Pal et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations
Song et al. Treatment of patients with relapsed or refractory mantle–cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase
Santarpia et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Awan et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Freise et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia
Kristeleit et al. A phase I–II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors
US20210106574A1 (en) Methods of Treating Cancer
AU2021218080B2 (en) Combination therapies for treating cancer
El Gnaoui et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
Clark et al. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models
Uppaluri et al. Biomarker and tumor responses of oral cavity squamous cell carcinoma to trametinib: a phase II neoadjuvant window-of-opportunity clinical trial
von Wahlde et al. Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer
Somaiah et al. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations
Park et al. Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis
Piulats et al. Orthoxenografts of testicular germ cell tumors demonstrate genomic changes associated with cisplatin resistance and identify PDMP as a resensitizing agent
Rosas-Plaza et al. Dual mTORC1/2 inhibition sensitizes testicular cancer models to cisplatin treatment
Pignata et al. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial
Green et al. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma
WO2020104598A1 (en) Method of predicting responsiveness of a gastrointestinal cancer patient to a chemotherapy treatment
BR112021014657A2 (pt) Métodos para tratar câncer de próstata com base em subtipos moleculares
Wang et al. Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials
Scott PARP inhibitors in advanced ovarian cancer: a review of long-term efficacy and survival rates
Liu et al. A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination